within Pharmacolibrary.Drugs.ATC.N;

model N05AE03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 0.011666666666666665,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0011666666666666668,
    Tlag           = 1800
  );

  annotation(Documentation(
    info ="<html><body><p>Sertindole is an atypical antipsychotic drug, previously used in the treatment of schizophrenia. Due to concerns related to QT interval prolongation and risk of cardiac arrhythmias, its use is restricted or withdrawn in several countries. It is approved in some European countries but not in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers (male and female) after repeated oral administration.</p><h4>References</h4><ol><li><p>Wong, SL, et al., &amp; Granneman, GR (1997). Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. <i>Clinical pharmacology and therapeutics</i> 62(2) 157–164. DOI:<a href=&quot;https://doi.org/10.1016/S0009-9236(97)90063-1&quot;>10.1016/S0009-9236(97)90063-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9284851/&quot;>https://pubmed.ncbi.nlm.nih.gov/9284851</a></p></li><li><p>Bundgaard, C, et al., &amp; Olsen, CK (2009). Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response. <i>Biopharmaceutics &amp; drug disposition</i> 30(4) 209–220. DOI:<a href=&quot;https://doi.org/10.1002/bdd.656&quot;>10.1002/bdd.656</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19475539/&quot;>https://pubmed.ncbi.nlm.nih.gov/19475539</a></p></li><li><p>Wong, SL, et al., &amp; Granneman, GR (1997). Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. <i>European journal of clinical pharmacology</i> 52(3) 223–227. DOI:<a href=&quot;https://doi.org/10.1007/s002280050278&quot;>10.1007/s002280050278</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9218930/&quot;>https://pubmed.ncbi.nlm.nih.gov/9218930</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05AE03;
